Prognostic significance of p53 immunostaining in epithelial ovarian cancer.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1994.12.1.64PMID 8270986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents.

  1993cited by this paper
• p53 function and dysfunction.

  1992cited by this paper
• The p53 tumour suppressor gene and product.

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• Regulation of the specific DNA binding function of p53.

  1992cited by this paper
• Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

  1992cited by this paper
• The p53 tumour suppressor gene and product.

  1992cited by this paper
• Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.

  1992cited by this paper
• Mutation of p53 gene in hepatocellular carcinoma in Taiwan.

  1992cited by this paper
• High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy

  1992cited by this paper
• Overexpression and mutation of p53 in epithelial ovarian cancer.

  1991cited by this paper
• Frequent allelic losses and mutations of the p53 gene in human ovarian cancer.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Molecular biology of ovarian cancer

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Toward the primary prevention of cancer.

  1991cited by this paper
• Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

  1990cited by this paper
• Mutations in the p53 gene occur in diverse human tumour types

  1989cited by this paper
• A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.

  1983cited by this paper
• Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

  1983cited by this paper
• Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle

  1975cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer

  2019cites this paper
• SUMMARY THE ROLE OF GROWTH AND PROLIFERATION FACTORS IN PROGRESS OF SEROUS AND MUCINOUS OVARIAN CARCINOMAS

  2018cites this paper
• ROLE OF P65 AND P53 EXPRESSION IN DIFFERENT STAGE AND GRADE OF OVARIAN CANCER

  2018cites this paper
• 2 years study on p 53 expression on serous and mucinous tumors of ovary

  2016cites this paper
• P53 over Expression in Ovarian Neoplasms - An Immuno Histochemical Study

  2015cites this paper
• THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.

  2015cites this paper
• Expression of LASP-1 in Epithelial Ovarian Cancer

  2015cites this paper
• Pathway Modulations and Epigenetic Alterations in Ovarian Tumorbiogenesis

  2014cites this paper
• TP53 mutations in myelodysplastic syndromes with deletion of 5q

  2013cites this paper
• A cytohistological study of p53 overexpression in ovarian neoplasms

  2012cites this paper
• Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors

  2012cites this paper
• P53 and Ki67 immunoexpression in mucinous malignant ovarian tumors.

  2012cites this paper
• Significance of Cell Cycle Regulatory Proteins as Malignant and Prognostic Biomarkers in Ovarian Epithelial Tumors

  2011cites this paper
• Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

  2011cites this paper
• OverinYüzeyEpitelyal-StromalTümörlerindeTp53Ekspresyonu veKi-67ProliferasyonİndeksiveHistopatolojikPrognostik Parametrelerleİlişkileri

  2011cites this paper
• Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients

  2010cites this paper
• Tp53 Expression and Ki-67 Proliferation Index in Surface Epithelial-Stromal Tumors of the Ovary and Their Relationship with the Histopathological Prognostic Parameters

  2010cites this paper
• The expression of clusterin, bax, p53, Ki-67, and apoptotic index in epithelial ovarian tumors.

  2010cites this paper
• Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies

  2010cites this paper
• Prognostic biomarkers in ovarian cancer

  2010cites this paper
• Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

  2009cites this paper
• University of Groningen Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer

  2009cites this paper
• Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers.

  2009cites this paper
• Modest effect of p 53 , EGFR and HER-2 / neu on prognosis in epithelial ovarian cancer : a meta-analysis

  2009cites this paper
• Influence of Reproductive Factors on Mortality after Epithelial Ovarian Cancer Diagnosis

  2009cites this paper
• Molecular markers in epithelial ovarian cancer: paving the way to innovative therapies

  2009cites this paper
• Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status.

  2009cites this paper
• Tumor suppressor genes.

  2009cites this paper
• The expression of HLA class I molecules and complement regulatory proteins in ovarian cancer

  2008cites this paper
• Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

  2008cites this paper
• Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival

  2008cites this paper
• Oligonucleotide microarray analysis of gene expression profiles followed by real-time reverse-transcriptase polymerase chain reaction assay in chronic active Epstein-Barr virus infection.

  2008cites this paper
• Utilization of a uniform grading system for interpreting serous ovarian cancer.

  2008cites this paper
• Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.

  2008cites this paper
• Drug Resistance The Clinical Perspective

  2007cites this paper
• Conditional inactivation of the BRCA1 tumour suppressor gene in the mouse ovarian surface epithelium in vitro and in vivo

  2007cites this paper
• Molecular Markers in Epithelial Ovarian Cancer

  2007cites this paper
• Immunologic markers of cancer progression and prognosis.

  2007cites this paper
• Biomarker discovery in epithelial ovarian cancer by genomic approaches.

  2007cites this paper
• Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.

  2007cites this paper
• Cell Cycle and Related Protein

  2007cites this paper
• Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses.

  2006cites this paper
• Ovarian cancer in younger vs older women: a population-based analysis

  2006cites this paper
• Que sait-on de la carcinogenèse ovarienne?

  2006cites this paper
• Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

  2006cites this paper
• Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.

  2006cites this paper
• Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy

  2005cites this paper
• Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.

  2005cites this paper
• The Relationship of p53 Accumulation and DNA Ploidy and Conventional Clinicopathological Prognostic Variables in Patients with Ovarian Carcinoma

  2005cites this paper
• Expression of the c‐Met in advanced epithelial ovarian cancer and its prognostic significance

  2005cites this paper
• p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity

  2005cites this paper
• Cyclooxygenase-2 in myometrium during parturition and in ovarian carcinoma

  2005cites this paper
• p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.

  2005cites this paper
• Aus der Klinik und Poliklinik für Gynäkologie des Universitätsklinikums Hamburg-Eppendorf

  2005cites this paper
• Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome

  2005cites this paper
• Mutational spectrum of p53 mutations in primary breast and ovarian tumors.

  2004cites this paper
• The clinical significance of p53 aberrations in human tumours

  2004cites this paper
• Critical evaluation of p53 as a prognostic marker in ovarian cancer

  2004cites this paper
• Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients.

  2004cites this paper
• Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma

  2004cites this paper
• Analysis of potential prognostic factors in 111 patients with ovarian cancer.

  2004cites this paper
• Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma

  2004cites this paper
• Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

  2004cites this paper
• Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance

  2004cites this paper
• Clinical value of molecular changes in ovarian carcinoma

  2004cites this paper
• Analyses of p53 expression pattern and BRCA mutations in patients with double primary breast and ovarian cancer

  2004cites this paper
• Prognostic factors in ovarian cancer: current evidence and future prospects

  2003cites this paper
• Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

  2003cites this paper
• Genetic abnormalities of cell proliferation, invasion and metastasis, with special reference to gynaecological cancers.

  2003cites this paper
• Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2003cites this paper
• Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

  2003influential citation
• c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.

  2003cites this paper
• Distinct subtypes of serous ovarian carcinoma identified by p53 determination.

  2003cites this paper
• Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium.

  2003cites this paper
• A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

  2003cites this paper
• Ovarian cancer and high-risk women-implications for prevention, screening, and early detection.

  2003cites this paper
• Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.

  2003cites this paper
• Tumor markers. An update approach for their prognostic significance. Part I.

  2003cites this paper
• Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins

  2003cites this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cites this paper
• Stages III and IV Invasive Epithelial Ovarian Carcinoma in Younger Versus Older Women: What Prognostic Factors Are Important?

  2003cites this paper
• Type I and type III collagen metabolites and peritoneal cells in predicting the clinical outcome of epithelial ovarian cancer patients

  2003cites this paper
• The Genetic Etiology of Sporadic Ovarian Cancer

  2003cites this paper
• Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.

  2002cites this paper
• Genetic and Molecular Changes in Serous Gynecological Carcinomas - comparison with other histological types, and clinical associations

  2002cites this paper
• Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma.

  2002cites this paper
• Molecular aspects of ovarian cancer.

  2002cites this paper
• P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer

  2002cites this paper
• P53 and Bcl‐2 as prognostic predictors in epithelial ovarian cancer

  2002cites this paper
• p53 mutation does not affect prognosis in ovarian epithelial malignancies

  2001cites this paper
• A prognostic model for ovarian cancer

  2001cites this paper
• p21 and p53 in ovarian carcinoma

  2001cites this paper
• Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

  2001cites this paper
• Prognostic Value of DNA Quantification in Early Epithelial Ovarian Carcinoma

  2001cites this paper
• Molecular and cytogenetic changes in ovarian carcinoma

  2001cites this paper
• P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma

  2001cites this paper
• Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

  2001cites this paper
• Parameters of differentiation and proliferation in adult granulosa cell tumors of the ovary.

  2001cites this paper
• Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma.

  2001cites this paper
• Correlation of p 53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer 1

  2001cites this paper